Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans

Wendy Ramey, BSPharm, RPh, CSP  |  Issue: February 2020  |  February 13, 2020

Back in the Office

How can a rheumatology office handle these situations proactively? First, it is effective for someone in the clinic to encourage and assist patients in enrolling in the manufacturer support programs available for bDMARDs and tsDMARDs.

Second, patient education is essential. Encourage patients to call their health plan and ask if there is a copay accumulator in place. This information is not given freely to prescribers, but must be available to patients. Suggest that your patient read their invoices from the specialty pharmacy and look at what their insurance is paying and what the copay card is paying. If the copay card is covering more than $2,000 for two months in a row, the chances of exhausting the copay card’s annual benefit needs to be investigated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Third, ensure that at least one clinic staff member has a working knowledge of the local commercial insurance carriers, what medications are preferred and which employers use copay accumulator programs.

Fourth, investigate options when a patient unknowingly exhausts the copay card benefits. Sometimes, patient assistance foundations can step in. Sometimes, the copay benefit can be extended. And sometimes, a manufacturer support program can assist.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Fifth, advocate for rheumatology patients and encourage patients to advocate for themselves. Providers can participate by using the advocacy resources available on the ACR/ARP website and contacting elected officials about this and other specific issues. Patients can participate by reaching out to their employer’s human resources department or contacting their state’s Department of Insurance or the National Association of Insurance Commissioners.

As new and specialized medications become more costly, insurers will demand patients share financial responsibility. Expect programs like copay accumulators and copay maximizers to affect more patients and make managing rheumatologic diseases more difficult. Knowing the playing field is key. 


Wendy Ramey, BSPharm, RPh, CSP, is a clinic-based specialty pharmacist at the University of Kentucky, Lexington, in the rheumatology program. She received her Specialty Pharmacist Certification in October 2016.

Author’s Personal Statement

I have a special interest in rheumatoid arthritis due to my own diagnosed RA in 2013. I feel a calling to help other patients find treatment regimens that will improve their quality of life by controlling the symptoms and side effects of their autoimmune diseases.

Page: 1 2 3 | Single Page
Share: 

Filed under:Drug UpdatesLegislation & AdvocacyPractice Support Tagged with:copay accumulatorscopay maximizerspharmacy benefit managers (PBMs)prior authorization

Related Articles

    A Primer on Copay Accumulator Programs

    June 17, 2022

    The growing use of copay accumulator programs, which restrict the application of patient assistance funds toward cost-sharing requirements, hurts patient access to life-changing treatments. This was one topic discussed during the ACR’s Advocacy Leadership Conference in D.C. this May.

    Copay Accumulator & Maximizer Programs Threaten Access to Treatment

    July 6, 2023

    As health insurance companies and third-party benefit managers continue to use copay accumulators and maximizers to shift the cost of specialty drugs to patients, the ACR continues to advocate against programs that limit copay assistance.

    ACR Leads Resolution to Address Copay Accumulator Policies at AMA House of Delegates Meeting

    November 6, 2020

    If passed, the ACR-authored resolution will direct the AMA to advocate for copay accumulator bans at state and federal levels. Several other specialties and state medical associations have joined the resolution as cosponsors.

    High Cost of Specialty Drugs Demands Action

    July 6, 2021

    Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences